Eledon Pharmaceuticals Stock Rises on Diabetes Trial Success

By EC Assets · Published 8 June 2026

Eledon Pharmaceuticals Inc. shares have seen a significant increase following positive results from its type 1 diabetes trial. The company reported updated data from an investigator-initiated islet transplant trial. This trial involved Tegoprubart in patients with Type 1 Diabetes (T1D). The positive results contributed to Eledon's stock surging 125% year-to-date. The trial, conducted at UChicago Medicine, showed promising results. All 12 diabetes patients achieved insulin independence. Analysts maintain a strong buy consensus and positive price targets for Eledon Pharmaceuticals. Type 1 diabetes is a condition resulting from the body's immune system attacking insulin-producing cells. NewcelX is also accelerating the clinical advancement of NCEL-101 for Type 1 Diabetes with Eledon Pharmaceuticals. This includes a Pre-IND meeting. Scientists are also developing cell therapy that cured the disease in mice. This article is intended for informational purposes only. It does not constitute investment advice.